EquityBulls

Latest News

Keywords Selected: SunPharmaceuticalIndustries

Stock Report

Sun Pharmaceutical Industries Ltd Update on US FDA Inspection at Mohali Facility
Sun Pharmaceutical Industries Ltd receives OAI from USFDA for Halol facility
Sun Pharma Chairman, Israel Makov to retire on completion of term
Sun Pharmaceutical Industries Ltd Q1 FY2023 consolidated PAT rises to Rs. 2060.88 crores
Sun Pharma and Cosmo Announce Territory Expansion of License and Supply Agreements for WINLEVI®
Sun Pharma Acquires Uractiv™ Portfolio from Fiterman Pharma in Romania
Sun Pharma to launch Brillo®, a first-in-class oral lipid-lowering drug in India
Sun Pharma announces US FDA Approval for Generic Mesalamine Extended Release Capsules
Sun Pharmaceutical Industries gets 10 observations from US FDA for Halol facility
Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck
Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting
Taro to acquire Alchemee from Galderma
Sun Pharmaceutical Industries Ltd declares interim dividend of Rs. 7
Sun Pharma Q3FY22 consolidated profit up at Rs. 2058.8 crores
Sun Pharma launches solution for dry eye treatment with NCELL™ technology in Canada
Sun Pharma receives DCGI approval for Molxvir® in India
Sun Pharma announces US FDA Approval for Generic Amphotericin B Liposome Injection
Sun Pharma arm DUSA to get $22.5 mn from Biofrontera for settlement of litigation
Sun Pharma geared to introduce Molnupiravir, licensed from MSD and Ridgeback, under the brand name Molxvir® in India
Sun Pharma announces availability of WINLEVI® (clascoterone) cream 1% in the U.S. for Topical Treatment of Acne Vulgaris
Sun Pharmaceutical Industries Ltd posts jump in Q2FY22 consolidated net profit to Rs. 2088.73 crore
Sun Pharma's PrILUMYA™ now available to help Canadians living with moderate-tosevere plaque psoriasis